Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Solaro

Showing results (111-120 of 140) with videos related to

Pageof 14
Sort By:
Journal of Neurology|April 4, 2022
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective studyAntonio Riccardo Buonomo, Giulio Viceconte, Massimiliano Calabrese, et al.
Journal of Neurology|February 15, 2022
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective studyAntonio Riccardo Buonomo, Giulio Viceconte, Massimiliano Calabrese, et al.
JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 19, 2021
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosisMassimiliano Di Filippo, Cinzia Cordioli, Simona Malucchi, et al.
Plos One|August 2, 2017
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)Silvia Messina, Claudio Solaro, Isabella Righini, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 27, 2020
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter studyFrancesco Patti, Clara Grazia Chisari, Claudio Solaro, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 7, 2024
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara G Chisari, Umberto Aguglia, Maria Pia Amato, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 15, 2020
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre studyClara Grazia Chisari, Claudio Solaro, Pasquale Annunziata, et al.
Neurology|October 7, 2020
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1aFrancesca Bovis, Tomas Kalincik, Fred Lublin, et al.
Journal of Neurology|June 28, 2021
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective studyClara G Chisari, Giancarlo Comi, Massimo Filippi, et al.
Pageof 14

Showing results (111-120 of 140) with videos related to

Sort By:
Pageof 14
Journal of Neurology|April 4, 2022
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective studyAntonio Riccardo Buonomo, Giulio Viceconte, Massimiliano Calabrese, et al.
Journal of Neurology|February 15, 2022
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective studyAntonio Riccardo Buonomo, Giulio Viceconte, Massimiliano Calabrese, et al.
JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 19, 2021
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosisMassimiliano Di Filippo, Cinzia Cordioli, Simona Malucchi, et al.
Plos One|August 2, 2017
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)Silvia Messina, Claudio Solaro, Isabella Righini, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 27, 2020
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter studyFrancesco Patti, Clara Grazia Chisari, Claudio Solaro, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 7, 2024
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara G Chisari, Umberto Aguglia, Maria Pia Amato, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 15, 2020
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre studyClara Grazia Chisari, Claudio Solaro, Pasquale Annunziata, et al.
Neurology|October 7, 2020
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1aFrancesca Bovis, Tomas Kalincik, Fred Lublin, et al.
Journal of Neurology|June 28, 2021
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective studyClara G Chisari, Giancarlo Comi, Massimo Filippi, et al.
Pageof 14